189 related articles for article (PubMed ID: 29350448)
1. Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single-institute experience.
Soliman SE; D'Silva CN; Dimaras H; Dzneladze I; Chan H; Gallie BL
Pediatr Blood Cancer; 2018 May; 65(5):e26931. PubMed ID: 29350448
[TBL] [Abstract][Full Text] [Related]
2. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin-associated ototoxicity in children with retinoblastoma.
Qaddoumi I; Bass JK; Wu J; Billups CA; Wozniak AW; Merchant TE; Haik BG; Wilson MW; Rodriguez-Galindo C
J Clin Oncol; 2012 Apr; 30(10):1034-41. PubMed ID: 22370329
[TBL] [Abstract][Full Text] [Related]
4. Long-term audiologic follow-up of carboplatin-treated children with retinoblastoma.
Geurtsen ML; Kors WA; Moll AC; Smits C
Ophthalmic Genet; 2017; 38(1):74-78. PubMed ID: 27050825
[TBL] [Abstract][Full Text] [Related]
5. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.
Jehanne M; Lumbroso-Le Rouic L; Savignoni A; Aerts I; Mercier G; Bours D; Desjardins L; Doz F
Pediatr Blood Cancer; 2009 May; 52(5):637-43. PubMed ID: 19148943
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ; Katzov-Eckert H; Dubé MP; Brooks B; Rassekh SR; Barhdadi A; Feroz-Zada Y; Visscher H; Brown AM; Rieder MJ; Rogers PC; Phillips MS; Carleton BC; Hayden MR;
Nat Genet; 2009 Dec; 41(12):1345-9. PubMed ID: 19898482
[TBL] [Abstract][Full Text] [Related]
7. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy.
Lambert MP; Shields C; Meadows AT
Pediatr Blood Cancer; 2008 Feb; 50(2):223-6. PubMed ID: 17278120
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
9. Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma.
Bhagat SP; Bass JK; White ST; Qaddoumi I; Wilson MW; Wu J; Rodriguez-Galindo C
Int J Pediatr Otorhinolaryngol; 2010 Oct; 74(10):1156-63. PubMed ID: 20667604
[TBL] [Abstract][Full Text] [Related]
10. [The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment].
Mironovich OL; Bliznetz EA; Garbaruk ES; Belogurova MB; Subora NV; Varfolomeeva SR; Kachanov DY; Shamanskaya TV; Markova TG; Polyakov AV
Vestn Otorinolaringol; 2018; 83(4):60-66. PubMed ID: 30113582
[TBL] [Abstract][Full Text] [Related]
11. Assessment of hearing in very young children receiving carboplatin for retinoblastoma.
Smits C; Swen SJ; Theo Goverts S; Moll AC; Imhof SM; Schouten-van Meeteren AY
Eur J Cancer; 2006 Mar; 42(4):492-500. PubMed ID: 16376542
[TBL] [Abstract][Full Text] [Related]
12. Challenges in interpreting the evidence for genetic predictors of ototoxicity.
Ratain MJ; Cox NJ; Henderson TO
Clin Pharmacol Ther; 2013 Dec; 94(6):631-5. PubMed ID: 24241639
[TBL] [Abstract][Full Text] [Related]
13. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.
Hagleitner MM; Coenen MJ; Patino-Garcia A; de Bont ES; Gonzalez-Neira A; Vos HI; van Leeuwen FN; Gelderblom H; Hoogerbrugge PM; Guchelaar HJ; Te Loo MW
PLoS One; 2014; 9(12):e115869. PubMed ID: 25551397
[TBL] [Abstract][Full Text] [Related]
14. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
Pussegoda K; Ross CJ; Visscher H; Yazdanpanah M; Brooks B; Rassekh SR; Zada YF; Dubé MP; Carleton BC; Hayden MR;
Clin Pharmacol Ther; 2013 Aug; 94(2):243-51. PubMed ID: 23588304
[TBL] [Abstract][Full Text] [Related]
15. Ototoxicity in retinoblastoma survivors treated with carboplatin based chemotherapy: A cross-sectional study of 116 patients.
Batra A; Thakar A; Bakhshi S
Pediatr Blood Cancer; 2015 Nov; 62(11):2060. PubMed ID: 26053139
[No Abstract] [Full Text] [Related]
16. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Siemens A; Brooks B; Rassekh SR; Meijer AJM; van den Heuvel-Eibrink MM; Xu W; Loucks CM; Ross CJD; Carleton BC;
Ther Drug Monit; 2023 Jun; 45(3):345-353. PubMed ID: 36917731
[TBL] [Abstract][Full Text] [Related]
17. Genetics of cisplatin ototoxicity: confirming the unexplained?
Boddy AV
Clin Pharmacol Ther; 2013 Aug; 94(2):198-200. PubMed ID: 23872836
[TBL] [Abstract][Full Text] [Related]
18. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.
Yang JJ; Lim JY; Huang J; Bass J; Wu J; Wang C; Fang J; Stewart E; Harstead EH; E S; Robinson GW; Evans WE; Pappo A; Zuo J; Relling MV; Onar-Thomas A; Gajjar A; Stewart CF
Clin Pharmacol Ther; 2013 Aug; 94(2):252-9. PubMed ID: 23820299
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of cisplatin ototoxicity by the audiometric curve in retinoblastoma].
Toral-Martinñon R; Collado-Corona MA; Mora-Magaña I; Leal-Leal C; Gutiérrez-Castrellón P; González-de Leo S
Cir Cir; 2006; 74(2):79-82. PubMed ID: 16887078
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of ototoxicity in young children receiving carboplatin for retinoblastoma.
Jehanne M; Mercier G; Doz F
Pediatr Blood Cancer; 2009 Dec; 53(6):1162. PubMed ID: 19479791
[No Abstract] [Full Text] [Related]
[Next] [New Search]
